FDA Warns Against Bowel Cleansing Drugs for Colonoscopy
Bowel cleansing products that contain sodium phosphate have received a stern warning from the FDA about the potential of the products to cause acute kidney damage. Two products available by prescription, Visicol and OsmoPrep have received "black box" warnings from the FDA. The over-the-counter bowel cleanser, Fleet Phospho-soda, is also not recommended for consumer use because of the same potential for kidney injury as seen in the prescription bowel cleansers.
The FDA reveals they have received 20 reports of sudden kidney injury within the past two years, associated with the use of OsmoPrep and Visicol. Both products were approved by the FDA in 2006. Since that time, nineteen cases of kidney failure have been confirmed by biopsy, occurring within hours or weeks after the prescriptions were used for bowel cleansing.
FDA officials claim that not everyone is at risk. Charles Ganley, MD, director of the FDA's Office of Nonprescription Products says, "The majority (of patients) don't run into problems." Those at risk include anyone over age 55, people with colon problems causing a delay in bowel evacuation, anyone with acute colitis, and those who are dehydrated.
Precautions are especially important for patients who take medication that already can affect the kidneys, including diuretics, ACE inhibitors (blood pressure medicine), and anti-inflammatory drugs (NSAIDS), such as Ibuprofen and Naproxen.
Polyethylene glycol preparations that can be safely used for bowel cleansing include Golytely, Colyte, Nulytely, Trilyte, and Halflytely, none of which contains sodium phosphate.
In January, 2014, the FDA also issued an alert for over the counter products containing sodium phosphate or sodium biphosphate, warning again of the risks of dehydration that can occur from taking more than the recommended dose. The products are sold for constipation and can be taken orally or used in enema preparations. An example is "Fleet" enema.